Skip to main content

Advertisement

SpringerLink
Log in

Mpl ligand or thrombopoietin: Biological activities

  • Published:
Biotherapy

Abstract

Thrombopoietin (TPO) or Mpl ligand is the primary physiological regulator of platelet production. This cytokine is the most potent stimulator of the proliferation and differentiation of MK progenitor and precursor cellsin vitro. It also acts additively or synergistically with several cytokines on progenitor cells from various hematopoietic lineages, including the primitive stem cells. The factor is an extremely potent thrombocytopoietic agent when administrated to normal animals, and it accelerates platelet and erythropoietic recovery in several models of myelosuppression. Phase I/II clinical trials are ongoing with no detectable adverse effects. Mpl ligand does not induce platelet aggregation, but it lowers the platelet sensitivity to physiological dose of agonists. In experimental mouse models, high and chronic dose of Mpl ligand results in myelofibrosis. TPO is constantly produced by the liver and the kidney; its plasmatic clearance occurs by binding to its receptor expressed on megakaryocytes and platelets. However, the full spectrum of the biological effects of this new cytokine is not fully understood, in particular its the role in the terminal stage of platelet production. In the near future, it is likely that new insights will be obtained in the physiopathological mechanisms underlying abnormal platelet production in human.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hoffman R. Regulation of megakaryocytopoiesis. Blood 1989; 74: 1196–1212.

    PubMed  CAS  Google Scholar 

  2. Burstein SA. Platelets and cytokines. Current Opinion Hematol 1994; 1: 373–380.

    CAS  Google Scholar 

  3. Vainchenker W, Debili N, Mouthon MA, Wendling F. Megakaryocytopoiesis: Cellular aspects and regulation. Critical reviews in Oncology/Hematology 1995; 20: 165–192.

    Article  PubMed  CAS  Google Scholar 

  4. de Gabriele G, Pennington DG. Regulation of platelet production. Brit. J. Haematol. 1967; 13: 210.

    Google Scholar 

  5. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720–2730.

    PubMed  CAS  Google Scholar 

  6. Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythemic sera. Acta Haematol (Basel) 1958; 20: 350–355.

    Article  CAS  Google Scholar 

  7. Souyri M, Vigon I, Penciolelli J-F, Heard J-M, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63: 1137–1147.

    Article  PubMed  CAS  Google Scholar 

  8. Vigon I, Mornon J-P, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. USA 1992; 89: 5640–5644.

    Article  PubMed  CAS  Google Scholar 

  9. Skoda RC, Seldin DC, Chiang M-K, Peichel CL, Vogt TF, Leder P. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO. J. 1993; 12: 2645–2653.

    PubMed  CAS  Google Scholar 

  10. Vigon I, Florindo C, Fichelson S, et al. Characterization of the murine Mpl proto-oncogene, a member of the hematopoietic cytokine receptor family: molecular cloning, chromosomal location and evidence for a function in cell growth. Oncogne 1993; 8: 2607–2615.

    CAS  Google Scholar 

  11. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82: 1395–1401.

    PubMed  CAS  Google Scholar 

  12. Debili N, Wendling F, Katz A, et al. The Mpl-Ligand or thrombopoietin or megakaryocyte growth and development factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995; 86: 2516–2525.

    PubMed  CAS  Google Scholar 

  13. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265: 1445–1447.

    Article  PubMed  CAS  Google Scholar 

  14. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that its a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117–1124.

    Article  PubMed  CAS  Google Scholar 

  15. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MPL ligand. Nature 1994; 369: 533–538.

    Article  PubMed  Google Scholar 

  16. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin and stimulation of platelet production in vivo. Nature 1994; 369: 565–568.

    Article  PubMed  CAS  Google Scholar 

  17. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J. Biochem. 1995; 118: 229–236.

    PubMed  CAS  Google Scholar 

  18. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc. Natl. Acad. Sci. USA 1994; 91: 11104–11108.

    Article  PubMed  CAS  Google Scholar 

  19. Wendling F, Maraskovsky E, Debili N, et al. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571–574.

    Article  PubMed  CAS  Google Scholar 

  20. Lok S, Foster DC. The structure, biology and potential therapeutic applications of recombinant thrombopoietin. Stem Cells 1994; 12: 586–598.

    Article  PubMed  CAS  Google Scholar 

  21. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511–521.

    PubMed  CAS  Google Scholar 

  22. Zeigler FC, de Sauvage F, Widmer HR, et al. In vitro, megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994; 84: 4045–4052.

    PubMed  CAS  Google Scholar 

  23. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85: 402–413.

    PubMed  CAS  Google Scholar 

  24. Choi ES, Hokom M, Bartley T. Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl, produces functional human platelets in vitro. Stem cells. 1995; 13: 317–322.

    PubMed  CAS  Google Scholar 

  25. Banu N, Wang J-F, Deng B, Groopman JE, Avraham H. Modulation of megakaryocytopoiesis by thrombopoietin: The c-Mpl ligand. Blood 1995; 86: 1331–1338.

    PubMed  CAS  Google Scholar 

  26. Horie K, Miyazaki H, Hagiwara T, et al. Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production. Exp. Hematol. 1997; 25: 169–176.

    PubMed  CAS  Google Scholar 

  27. Choi ES, Hokom MM, Chen J-L, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Brit. J. Haematol. 1996; 95: 227–233.

    CAS  Google Scholar 

  28. Ito T, Ishida Y, Kuriya S-I. Recombinant human c-mpl ligand is not a direct stimulator of proplatelet formation in mature human megakaryocytes. Brit. J. Haematol. 1996; 94: 387–390.

    Article  CAS  Google Scholar 

  29. Berardi A, Wang A, Levine JD, Lopez P, Scadden DT. Functional isolation and characterization of human hematopoietic stem cells. Science 1995; 267: 104–108.

    Article  PubMed  CAS  Google Scholar 

  30. Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with Steel Factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996; 87: 4544–4551.

    PubMed  CAS  Google Scholar 

  31. Sitnicka E, Lin N, Priestley GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996; 87: 4998–5005.

    PubMed  CAS  Google Scholar 

  32. Itoh R, Katayama N, Kato T, et al. Activity of the ligand for c-mpl, thrombopoietin, in early haemopoiesis. Brit. J. Haematol. 1996; 94: 228–235.

    Article  CAS  Google Scholar 

  33. Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995; 86: 419–431.

    PubMed  CAS  Google Scholar 

  34. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Recombinant thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors. Blood 1995; 86: 2494–2499.

    PubMed  CAS  Google Scholar 

  35. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 1996; 88: 429–436.

    PubMed  CAS  Google Scholar 

  36. de Sauvage FJ, Carver-Moore K, Luoh S-M, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J. Exp. Med. 1996; 183: 651–656.

    Article  PubMed  Google Scholar 

  37. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-mpl. Blood 1996; 87: 2162–2170.

    PubMed  CAS  Google Scholar 

  38. Carver-Moore K, Broxmeyer HE, Luoh S-M, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 1996; 88: 803–808.

    PubMed  CAS  Google Scholar 

  39. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand, thrombopoietin. Nature 1994; 369: 568–571.

    Article  PubMed  CAS  Google Scholar 

  40. Ulich TR, del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86: 971–976.

    PubMed  CAS  Google Scholar 

  41. Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86: 54–59.

    PubMed  CAS  Google Scholar 

  42. Hokom MM, Lancey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486–4492.

    PubMed  CAS  Google Scholar 

  43. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996; 97: 2145–2151.

    PubMed  CAS  Google Scholar 

  44. Fibbe WE, Heemskerk DPM, Laterveer L, et al. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86: 3308–3313.

    PubMed  CAS  Google Scholar 

  45. Kaushansky K, Broudy VC, Grossmann A, et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J. Clin. Invest. 1995; 96: 1683–1687.

    Article  PubMed  CAS  Google Scholar 

  46. Grossmann A, Lenox J, Deisher TA, et al. Synergistic effects of thrombopoietin and granulocyte colony-stimulating factor on neutrophil recovery in myelosuppressed mice. Blood 1996; 88: 3363–3370.

    PubMed  CAS  Google Scholar 

  47. Molineux G, Hartley CA, McElroy P, McCrea C, McNiece IK. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 1996; 88: 1509–1514.

    PubMed  CAS  Google Scholar 

  48. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 1996; 88: 366–376.

    PubMed  CAS  Google Scholar 

  49. Basser RL, Rasko JEJ, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHUMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279–1281.

    Article  PubMed  CAS  Google Scholar 

  50. O’Malley CJ, Rasko RL, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to human stimulates the production of functional platelets that show no evidence of in vitro activation. Blood 1996; 88: 3288–3298.

    PubMed  CAS  Google Scholar 

  51. Archimbaud E, Ottmann O, Lui Yin JA, et al. A randomised, double-blind, chemotherapy for adults with de-novo acute myeloid leukaemia (AML): Early results. Blood 1996; 88(Supplement 1): 447.

    Google Scholar 

  52. Vadhan-Raj S, Patel S, Broxmeyer HE, et al. Phase I–II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I). Blood 1996; 88(Supplement 1): 448.

    Google Scholar 

  53. Ulich TR, Del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF- induced megakaryocyte hyperplasia in mice. Blood 1996; 87: 5006–5015.

    PubMed  CAS  Google Scholar 

  54. Yan X-G, Lacey D, Flechter F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-Ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995; 86: 4025–4033.

    PubMed  CAS  Google Scholar 

  55. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996; 88: 402–409.

    PubMed  CAS  Google Scholar 

  56. Villeval J-L, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hemopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood (in press).

  57. Ohwada A, Rafii S, Moore MAS, Crystal RG. In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation- and chemotherapy-induced bone marrow suppression. Blood 1996; 88: 778–784.

    PubMed  CAS  Google Scholar 

  58. Zhou W, Toombs CF, Zou Y, Guo J, Robinson MO. Transgenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-Fluorouracil or antiplatelet serum treatment. Blood 1997; 89: 1551–1559.

    PubMed  CAS  Google Scholar 

  59. Miyakawa Y, Oda A, Druker BJ, et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus Kinase 2 and She in human blood platelets. Blood 1995; 86: 23–27.

    PubMed  CAS  Google Scholar 

  60. Miyakawa Y, Oda A, Druker BJ, et al. Thrombopoietin induces tyrosine phosphorylation of stat3 and stat5 in human blood platelets. Blood 1996; 87: 439–446.

    PubMed  CAS  Google Scholar 

  61. Toombs CF, Young CH, Glaspy JA, Vamum BC. Recombinant human megakaryocyte growth and development factor (MGDF) moderately enhances ex vivo platelet aggregation by a receptor dependent mechanism. Thrombosis Research 1995; 80: 23–33.

    Article  PubMed  CAS  Google Scholar 

  62. Chen J, Herced-Harjacek L, Groopman JE, Grabarek J. Regulation of platelets activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86: 4054–4062.

    PubMed  CAS  Google Scholar 

  63. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87: 1833–1844.

    PubMed  CAS  Google Scholar 

  64. Zauli G, Bassini A, Vitale M, et al. Thrombopoietin enhances the αIIbβ3- dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase. Blood 1997; 89: 883–895.

    PubMed  CAS  Google Scholar 

  65. Shimada Y, Kato T, Ogami K, et al. Production of thrombopoietin (TPO) by rat hepatocytes and hepatoma cell lines. Exp Hematol 1995; 23: 1388–1396.

    PubMed  CAS  Google Scholar 

  66. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood 1996; 89: 101–107.

    Google Scholar 

  67. McDonald TP. Thrombopoietin: its biology, clinical aspects and possibilities. Hematol/Oncol 1992; 14(The Am. J. Pediatr.): 8–21.

    Article  CAS  Google Scholar 

  68. de Gabriele G, Pennington DG. Physiology of the regulation of platelet production. Brit J of Haemat 1967; 13: 202.

    Google Scholar 

  69. Kuter DJ, Rosenberg RD. Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 1994; 84: 1464–1472.

    PubMed  CAS  Google Scholar 

  70. Cohen-Solal K, Villeval J-L, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcript during thrombocytopenia and thrombocytosis. Blood 1996; 88: 2578–2584.

    PubMed  CAS  Google Scholar 

  71. Fielder PJ, Gumey AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154–2161.

    PubMed  CAS  Google Scholar 

  72. Stoffer R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87: 567–573.

    Google Scholar 

  73. Gurney AL, Kuang W-J, Xie M-H, Malloy BE, Eaton DL, de Sauvage FJ. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995; 85: 981–988.

    PubMed  CAS  Google Scholar 

  74. Chang M-S, Hsu R-Y, McNinch J, Copeland N G,, Jenkins N A,. The gene for murine megakaryocyte growth and development factor (Thrombopoietin,Tpo) is located on mouse chromosome 16. Genomics 1995; 26: 636–637.

    Article  PubMed  CAS  Google Scholar 

  75. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695–704.

    Article  PubMed  CAS  Google Scholar 

  76. Mukai HY, Kojima H, Todokoro K, et al. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost 1996; 76: 675–678.

    PubMed  CAS  Google Scholar 

  77. Ichikawa N, Ishida F, Shimodaira S, Tahara T, Kato T, Kitano K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenia purpura. Thromb Haemost 1996; 76: 156–160.

    PubMed  CAS  Google Scholar 

  78. McCarthy JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668–3675.

    Google Scholar 

  79. Nagahisa H, Nagata Y, Ohnuki T, et al. Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation. Blood 1996; 87: 1309–1316.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM U362, Institut Gustave Roussy, PR1, 39 Rue Camille Desmoulins, 94805, Villejuif-Cedex, France

    Françoise Wendling, Karine Cohen-Solal, Jean-Luc Villeval, Najet Debili & William Vainchenker

Authors
  1. Françoise Wendling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karine Cohen-Solal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Luc Villeval
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Najet Debili
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William Vainchenker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Françoise Wendling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wendling, F., Cohen-Solal, K., Villeval, JL. et al. Mpl ligand or thrombopoietin: Biological activities. Biotherapy 10, 269–277 (1998). https://doi.org/10.1007/BF02678547

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02678547

Key words

Search

Navigation